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The parenteral route is considered to be the gold standard for
vaccination1e4. However, there are certain drawbacks associated
with parenteral immunization. Challenges such as needle phobia,
pain and redness at the site of injection and transmission of in-
fectious diseases due to needle stick injuries are some of the issues
related to parenteral immunization. Besides, for diseases such as
influenza, that do spread via the respiratory tract, parenteral im-
munization fails to elicit a potent local mucosal immune
response5,6. Hence, for such infectious diseases, respiratory tract
administration might be an attractive alternative to parenteral
administration. Even for non-airborne transmitted infectious dis-
eases, for example hepatitis B, respiratory tract immunization,
particularly via the pulmonary route, might be advantageous due
to its non-invasive nature, large surface area for immune response
induction and presence of abundant antigen presenting cells.
It can be hypothesized that the efficacy of immunization via the
pulmonary route depends on number of factors including the site
of deposition within the respiratory tract as well as the type of
vaccine used. For diseases that do spread via the respiratory tract
such as influenza and tuberculosis, both upper/central airways and
deep lung deposition led to the development of considerable im-
mune responses. However, Minne et al.7 and Todoroff et al.8
claimed with a liquid formulation that deep lung deposition was
superior in terms of induction of immune responses. Despite that
Bhide et al.9 recently demonstrated in cotton rats that the site of
deposition of influenza vaccine within the respiratory tract holds
minor relevance in the protective efficacy against a challenge with
a live virus. However, in the study of Bhide et al.9 deep lung
deposition was achieved with a liquid formulation, while trachea/
central airways deposition was achieved with a powder formula-
tion9. Thus, the physical state of the vaccine might also have
played a role in this study. Therefore, it is vital to further inves-
tigate whether the same conclusion holds true when powders are
targeted deep into the lungs. Furthermore, it is unknown whether
the site of deposition within the respiratory tract is of importance
for diseases that do not spread via the respiratory tract such as
hepatitis B. In principle, however, the antigen should be targeted
to that part of the respiratory tract where there is an optimal in-
duction of immune responses. The site of antigen deposition
within the respiratory tract will be influenced by the physical form
of the formulation, the delivery device used for administration and
for human vaccination also the inhalation manoeuvre. Vaccines for
pulmonary administration can be formulated as liquids and as dry
powders10e12. However, due to their long term stability at ambient
temperature, ease in stockpiling and possibility of being readily
available for mass vaccination, dry powder vaccine formulations
are preferred13,14. For deep lung deposition, a dry powder
formulation with an aerodynamic particle size distribution of
1e5 mm is required. In addition, a delivery device is required that
does not only efficiently disperse the powder particles in the
inhaled air stream but also delivers the aerosol particles at a low
velocity. High velocity and large size particles would either be
exhaled or deposited in the upper airways. For animal studies, the, Pulmonary immunization: depositio
0.1016/j.apsb.2019.05.003only commercially available (now discontinued) delivery device is
an insufflator developed by Penn-Century (Penn-Century, Wynd-
moor, USA). Unfortunately, this device has shown to deliver large
agglomerates of powder particles at a high velocity, thereby
depositing powder particles only in the trachea/central airways
and not in the deep lungs9,15,16. A newly developed device, Pre-
ciseInhale, has shown to cause less tracheal deposition as
compared to the insufflator17. However, one of the major limita-
tions associated with this device is the use of high-pressure pulse
for the dispersion of dry powders. In a study of Lexmond et al.18,
this resulted in the crystallization of amorphous spray-dried
products thereby forming large agglomerates. As a consequence,
the emitted fraction was extremely low (<1%). Recently, Tonnis
et al.16 described an in-house built aerosol generator for pulmo-
nary administration of dry powders to animals. Approximately
17% of the loaded spray-dried product was emitted from the
loading chamber, hence it is assumed that the aerosol generator
did not affect the amorphous state of the powder during disper-
sion. In addition, the aerosol generator was found to be suitable to
target lower regions of the respiratory tract, i.e., deep lungs. Thus,
by using the insufflator and the aerosol generator, targeting dry
powder formulations to the trachea/central airways and to the deep
lungs, respectively, is feasible. This enables research regarding the
preferred site of antigen deposition within the respiratory tract for
different vaccines.
The aim of the current study was to investigate the effect of the
site of antigen deposition within the respiratory tract on the im-
mune response in mice. For this, influenza and hepatitis B vaccine
liquid formulations were fluorescently labeled, spray-dried into
powder formulations and targeted to different regions of the res-
piratory tract of mice. Imaging system was used to verify trachea/
central airways deposition by insufflator and deep lungs deposi-
tion by the aerosol generator. Immune responses induced by the
spray-dried formulations deposited in different parts of the res-
piratory tract were compared to investigate the best site that
should be targeted for a particular vaccine candidate.
2. Materials and methods
2.1. Vaccines
Influenza subunit vaccine (A/California/7/2009 H1N1) was kindly
provided by Abbott, Weesp, Netherlands and hepatitis B surface
antigen was a generous gift from Serum Institute of India, Pune,
Maharashtra, India.
2.2. Labeling of influenza and hepatitis B vaccines
Influenza and hepatitis B vaccines were fluorescently labeled with
a near-infrared fluorescent dye VivoTag 680XL (PerkinElmer,
Walthman, MA, USA) as per the instructions provided by
the manufacturer. Briefly, 1 mL of influenza subunit vaccine
(153 mg/mL) was mixed with 4.6 mL of Vivo Tag (25 mg/mL) and
100 mL of 1 mol/L NaHCO3 solution. For hepatitis B, 91 mL of the
vaccine solution (1.1 mg/mL) was mixed with 1.5 mL of Vivo-Tagn site is of minor deposition is crucial for hepatitis B vaccination, Acta
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constant shaking at room temperature, the unbound fluorophore
was removed by passing the mixtures through Zeba Spin Desalt-
ing Columns (ThermoScientific, Rockford, IL, USA). In order to
calculate the degree of labeling, the concentration of labeled
vaccine and dye was determined at 280 and 668 nm, respectively.
Fluorophore cross-talk at 280 nm was adjusted by subtracting 16%
of the absorbance at 668 nm from the absorbance at 280 nm. It
was calculated that on average 4 or 3 dye molecules were bound to
each influenza and hepatitis B vaccine molecule, respectively.
2.3. Spray drying
Labeled and unlabeled liquid influenza and hepatitis B vaccine
formulations were spray-dried together with inulin (4 kDa, Sen-
sus, Roosendaal, Netherlands), which was used as a stabilizer/
bulking agent. A Bu¨chi B-290 Mini Spray Dryer (Bu¨chi, Flawil,
Switzerland) equipped with a standard two fluid nozzle was used
to spray dry liquid vaccine formulations. The mixture of liquid
vaccine formulations and inulin (prepared in distilled water) was
formulated (influenza subunit vaccine:inulin 1:100 (w/w); hepati-
tis B surface antigen:inulin 1:250 (w/w)) to obtain a final solid
concentration of 50 mg/mL. The mixture was pumped at a speed
of 5 mL/min and at an inlet temperature of 100 C leading to an
outlet temperature of 58 C. An atomizing airflow was set to 500
Ln/h with an aspirator setting of 100%.
2.4. Scanning electron microscopy
Scanning electron microscopy was done as described previously19.
Briefly, images were captured using a JEOL JSM 6301-Micro-
scope (JEOL, Tokyo, Japan). Vaccine powders were placed on a
carbon tape on a metal disc and coated with 30 nm of gold/
palladium using a Leica EM LCD250 sputtering device (Leica
Microsystems, Rijkswijk, The Netherlands).
2.5. Laser diffraction
The primary particle size distribution of spray-dried powders was
determined by laser diffraction analysis. A pressure of 1 bar was
used to disperse spray-dried powders using a RODOS disperser
(Sympatec, Clausthal-Zellerfeld, Germany). The start of the
measurements was triggered on an optical signal of 0.2% on
channel 30, and the measurements were stopped either after the
signal decreased to a value lower than 0.2% on the same channel
for a period of 1 s, or after 3 s of real measurement time. A
100 mm lens was used and the particle size distribution was
calculated using the Fraunhofer theory.
The particle size distribution of the powders was also analyzed
after dispersion of powders by the insufflator (model DP-4M;
Penn-Century, Wyndmoor, PA, USA) and aerosol generator. The
particle size dispersed from the insufflator was determined ac-
cording to the procedure of Hoppentocht et al.20 Briefly, the
insufflator was mounted on an in-house mounting plate and loaded
with 1 mg of spray-dried powder. The tip of the insufflator was
placed in the front of laser beam and the powders were dispersed
using an air pulse of 200 mL using an AP-1 air pump (Penn-
Century). Like dispersion from the RODOS, a similar 100 mm
lens was used.
The particle size distribution of the powders dispersed from the
aerosol generator was determined by dispensing powders in the
collection chamber of the aerosol chamber. A fraction of thesePlease cite this article as: Tomar J et al., Pulmonary immunization: depositio
Pharmaceutica Sinica B, https://doi.org/10.1016/j.apsb.2019.05.003powders was allowed to escape through a small tube with its tip
placed in the front of laser beam (see following section “in-vivo
deposition study”).
2.6. In-vivo deposition study
2.6.1. Powder administration by insufflator and the aerosol
generator
Animal experiments were approved by The Institutional Animal
Care and Use Committee of the University of Groningen, Gro-
ningen, The Netherlands (permit number: 6870AE). The animals
were administered with labeled vaccine powders only once. For
each vaccine candidate, 15 specific pathogen-free 8e10 week-old
BALB/c mice (Envigo, Horst, The Netherlands) were randomly
divided into three groups with 6 animals/group except for control,
which had 3 animals/group. Mice were anaesthetized by an
intraperitoneal injection of ketamine and dexdormitor and were
intubated with an AutoGrade catheter (20G, BD Insyte Auto-
guard, BD, Breda, The Netherlands). For the administration of dry
powders to trachea/central airways, the insufflator was loaded with
1 mg of labeled spray-dried powders containing either 10 mg
influenza subunit vaccine or 4 mg of hepatitis B surface antigen.
The delivery tube (internal diameter: 0.5 mm) was passed through
the trachea and the tip of the delivery tube was placed at the
bifurcation of trachea, i.e., carina. An AP-1 air pump was used to
disperse powders with three puffs of 200 mL of air/puff in
approximately 2 s. Thus, dispersion in this way led to a flow rate
of 0.1  103 L/s.
The amount of the powder thatwas dispersed from the insufflator
was determined by weighing the insufflator before and after
administration. It was found that 0.81  0.27 mg (average 
standard deviation) of spray-dried powder was dispersed from the
insufflator.
The pictorial representation of assembly and administration by
aerosol generator has been shown by Tonnis et al.16 Powders were
administered using the similar procedure as described by Tonnis
et al.16 Briefly, this aerosol generator contains an air classifier as
the powder disperser. The powder compartment of the aerosol
generator was filled with approximately 180 mg of spray-dried
vaccine formulation and was positioned on top of the air classi-
fier, thereby closing the air inlet to the aerosol generator. There-
after, the pressure inside the aerosol generator was lowered after
which the valve to the vacuum pump was closed. Next, the air inlet
was opened to allow air to flow freely through the powder
compartment into the air classifier and finally into the particle
collection chamber. Aerosols were generated and the intubated
mouse was then connected to the aerosol generator via an intu-
bation needle (internal diameter: 1.1 mm). A syringe was used to
deliver 3 mL of air during the time period of 1 min; this air was
introduced to deliver aerosols from the aerosol chamber to the
lungs of intubated mouse. The delivery of 3 mL of air in 1 min
corresponds to a flow rate of 0.5  104 L/s which is 2 times less
than the flow rate determined from the insufflator (0.1  103 L/s).
In addition, the internal diameter of the delivery tube used for
insufflator (0.5 mm) was 2.2 times smaller than that used for
aerosol generator (1.1 mm). This means that the aerosol generator
tubing has 4.8 times larger cross-sectional area for powder flow
than the tube of the insufflator. Hence, the cumulative effect of 2
times slower flow rate of aerosol generator and 4 times greater
cross-sectional flow area implies that the particles dispersed from
the aerosol generator travelled with 9.7 times lower velocity than
those dispersed from the insufflator.n site is of minor deposition is crucial for hepatitis B vaccination, Acta
4 Jasmine Tomar et al.
+ MODELFor the determination of dose dispersed from the aerosol
generator, the powder residues that remained in the dose
compartment, air classifier and aerosol chamber were collected. It
was found that 0.56  0.11 mg (average  standard deviation) of
the spray-dried powders were emitted from the aerosol generator.
2.7. In-vivo imaging system (IVIS)
Immediately after administration of fluorescently labeled vaccine
by the insufflator or aerosol generator, animals were sacrificed and
their lungs along with trachea were taken out. Lungs were either
used as such or dissected into lung lobes. The entire lungs or
dissected lung lobes were placed in petri-dishes and the emitted
fluorescent signal was determined by IVIS (PerkinElmer, Wal-
tham, MA, USA). An excitation wavelength of 675 nm was used
to measure fluorescent emission at 720 nm. The intensity of the
emitted light (photons/s/cm2/steradian) was quantified using
Living Image Software v3.2 (PerkinElmer, Waltham, MA, USA).
Fluorescent intensities determined in the lungs of non-vaccinated
animals (negative control) were subtracted from the fluorescent
intensities of vaccinated animals. Due to anatomical proximity of
heart with lungs, hearts of vaccinated as well as non-vaccinated
animals were also taken out to determine whether the adminis-
tration was indeed successful in lungs.
To further quantify the deposition of powder vaccine formu-
lations in trachea/central airways vs. deep lungs, each lung lobe
was divided into two equal halves by area with a region of interest
circular in shape. No clear distinction is described in the literature
in between central airways and deep lungs of mice, therefore, this
region of interest of specific dimensions (described as above) was
used for all vaccinated as well as non-vaccinated animals. The
sum of the fluorescent intensities emitted from the central parts of
lung lobes along with trachea was taken as trachea/central air-
ways. For deep lungs, the sum of the fluorescence intensity of a
region of interest targeting central airways was subtracted from
the total fluorescence intensity of all the lung lobes.
2.8. Immunization and sample collection
For each vaccine candidate, 21 specific pathogen-free 8e10 week-
old BALB/c mice (Envigo) were randomly divided into 4 groups
with 6 animals/group except for control which had 3 animals/
group. Mice were anaesthetized by an intraperitoneal injection of
ketamine and dexdormitor and were intubated with an AutoGrade
cathether (20G, BD Insyte Autoguard, BD, Breda, The
Netherlands). Animals were immunized twice, i.e., on day 0 and
day 14 with unlabeled vaccine powders.
After immunization, antisedan was administered subcutane-
ously for awakening of the animals. After awaking, mice were
kept in a recovery incubator with a temperature of 25 C for 2 h.
The same procedure was repeated on day 14. On day 14 and day
28, blood was collected by cheek puncture and cardiac puncture,
respectively. On day 28, lung washes were collected by flushing
lungs with 1 mL of PBS containing complete protease inhibitor
cocktail tablets (Roche, Almere, The Netherlands).
2.9. ELISA
For influenza, sera and lung washes were used for the determi-
nation of influenza specific IgG and IgA titers. ELISA plates
(Grenier Bio-One, Alphen aan den Rijn, The Netherlands)
were coated overnight with 500 ng/well of subunit influenzaPlease cite this article as: Tomar J et al., Pulmonary immunization: depositio
Pharmaceutica Sinica B, https://doi.org/10.1016/j.apsb.2019.05.003vaccine (A/california/H1N1) at 37 C. ELISA was performed as
described previously21. Synergy HT plate reader (BioTek,
Winooski, VT, USA) was used to measure absorbance at 492 nm.
Average IgG serum titers were calculated by determining the log10
of the reciprocal of the sample dilution corresponding to an
absorbance of 0.2 at 492 nm. IgA and IgG levels in bron-
chioalveolar lavages (BAL) are presented as average of the
absorbance at 492 nm for undiluted lung washes. For hepatitis B,
sera were used for the determination of hepatitis B specific IgG,
IgG1 and IgG2a antibody titers. ELISA plates were coated over-
night at room temperature with 0.2 mg of hepatitis B surface an-
tigen/per well. The ELISA procedure was followed as described
by Hirschberg et al.22 Absorbance was measured at 415 nm and
titers were calculated as the reciprocal of the sample dilution
corresponding to an absorbance of 0.2 at 415 nm. For BAL IgG,
average absorbance measured at 415 nm for undiluted lung
washes was plotted.
2.10. Statistics
ManneWhitney U test (two tailed) was used to test if the differ-
ences between two groups tested for different parameters were
significant. A P value of less than 0.05 was considered significant.
P values less than 0.05, 0.01, and 0.001 are denoted by *, ** and
***, respectively. Graphs were plotted using GraphPad Prism 5
software (GraphPad Software, La Jolla, San Diego, CA, USA).
3. Results
3.1. Physical characteristics of vaccine powders
The primary particle size distribution and the morphology of
influenza and hepatitis B powders were determined. Laser
diffraction analysis following dispersion by RODOS showed that
both powder formulations had median diameters (X50 values)
between 2.2 and 2.7 mm (Table 1) and 90% total powder volume
(X90) was in particles smaller than 6 mm. The primary particle size
distribution was compared to the particle size obtained by
dispersion from the insufflator and the aerosol generator. When
these powders were dispersed from the insufflator and aerosol
generator, the average geometric particle size was found to be
4.7e5.5 mm and 7.3e9.1 mm, respectively (Table 1). X50 values of
the powders dispersed from aerosol generator were found to be
larger than that of insufflator. Apparently, agglomerates were
broken up to a certain extent in both cases, but with insufflator
more efficiently. However, X90 values of the powder particles
dispersed from insufflator and aerosol generator were found to be
comparable (20.5e21.2 mm for the aerosol generator and
20.7e21.2 mm for the insufflator) (Table 1). This implies that
majority of the particles (X90) had size  21.2 mm both for the
insufflator and the aerosol generator.
Scanning electron microscope images show that the spray-
dried vaccine powders had intact spherical particles (Fig. 1A
and B).
3.2. In vivo deposition study
To assess the deposition of powder formulations dispersed from
the insufflator and aerosol generator in the trachea/lung lobes of
mice, imaging was performed on intact as well as dissected lung
lobes. A schematic diagram of trachea and lung lobes highlighting
central airways and deep lungs is shown in Fig. 2A. IVIS imagesn site is of minor deposition is crucial for hepatitis B vaccination, Acta
Table 1 Laser diffraction particle size distributions of labeled- and unlabeled-vaccine powders dispersed from RODOS, insufflator and
aerosol generator.
Disperser Geometric particle size
Influenza Hep-B
X10 X50 X90 X10 X50 X90
RODOS 0.90.04 2.20.1 5.50.06 1.20.07 2.70.09 5.80.1
Insufflator 1.50.02 4.70.05 20.70.07 1.60.02 5.50.02 210.03
Aerosol generator 2.10.04 7.50.09 20.50.03 2.40.05 8.90.1 21.20.05
Data are average  standard error of the mean (n Z 9).
Figure 1 Physical characteristics of vaccine powders. Scanning electron microscope images of spray-dried influenza (A) and hepatitis B (B)
vaccine powders at a magnification of 500  (Scale bar Z 50 mm) and 5000  (Scale bar Z 5 mm).
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upon dispersion from the insufflator is the trachea as it showed
bright yellow fluorescent spots (Fig. 2B and D). Upon dissection
of lungs into trachea and individual lung lobes, a small amount of
the powder also seemed to be deposited in the central parts of lung
lobes (Fig. 2B and D). However, when the powders were dispersed
from the aerosol generator, fluorescence signals of about the same
intensity were emitted from the entire lungs (Fig. 2B and D).
Further, upon dissection of the lungs, comparatively, a more ho-
mogenous distribution of powder could be determined in trachea
and lung lobes; no bright yellow fluorescent spots were visible
throughout the lung (Fig. 2B and D).
Upon quantification, it was found that both influenza and
hepatitis B powder vaccine formulations, upon dispersion from the
insufflator, were deposited in the trachea/central airways (100%).
Not even a minor fraction of the powder particles did seem to
penetrate into the peripheral parts of the lungs (Fig. 2C and E).
However, when these powders were dispersed from the aerosol
generator, significantly lower amounts of powders, approximately
55%e58%, were found to be deposited in the trachea/central
airways whereas the amount that penetrated the deep lung was
found to be about 42%e45% (Fig. 2C and E). Hence, with the
aerosol generator, a homogenous distribution of powder formu-
lations between the trachea/central and peripheral airways could
be obtained (Fig. 2C and E). These findings are in line with the
results obtained by Tonnis et al.16 who administered labeled
ovalbumin powders to mice using the insufflator and aerosol
generator.
3.3. Influence of site of deposition on immune responses:
Influenza
The influence of deposition of influenza vaccine formulations in
trachea/central airways and deep lungs was investigated by eval-
uating systemic and mucosal immune responses against influenza
subunit vaccine. Lung washes were collected on day 28 whereas
sera were taken both on day 14 and day 28. The intramuscularPlease cite this article as: Tomar J et al., Pulmonary immunization: depositio
Pharmaceutica Sinica B, https://doi.org/10.1016/j.apsb.2019.05.003(i.m.) group was used as the positive control whereas untreated
animals were the negative control group. On day 14, majority of
the vaccinated animals had developed anti-influenza serum IgG
titers. It was found that influenza vaccine powders targeted to
trachea/central airways by the insufflator led to the development
of comparable serum IgG titers as deep lung targeted vaccine
administered via the aerosol generator (Fig. 3A). Likewise, upon
evaluation of serum IgG titers at day 28, considerable IgG titers of
similar magnitude were found for animals vaccinated with the
insufflator and aerosol generator (Fig. 3B).
Lung washes collected on day 28 were evaluated for IgG as
well as IgA titers. Immunization with powder formulations via the
pulmonary route led to the development of low IgG titers; how-
ever, these were found to be equivalent for powder formulations
administered via the insufflator or aerosol generator (Fig. 3C). In
addition, lung IgA titers of comparable magnitude were found in
mice treated with influenza subunit vaccine powders targeted to
trachea/central airways or those treated with vaccine targeted to
the deep lungs (Fig. 3D). As expected, no lung IgA titers could be
detected by i.m. vaccination with influenza (Fig. 3D) which is in
line with earlier reports12,19,23.
3.4. Influence of site of deposition on immune responses:
Hepatitis B
The influence of hepatitis B powder deposition in the trachea/
central airways vs. deep lung on the immune responses was
evaluated. Systemic immune responses were evaluated both on
day 14 and day 28. On day 14, only 2 out of 12 animals pul-
monary immunized with powder formulation of hepatitis B, had
developed serum IgG titers (Fig. 4A). For these 2 animals,
powder vaccine was targeted deep into the lungs using the
aerosol generator. None of the animals that had trachea/central
airways deposition achieved by insufflator, had any IgG titers in
their sera (Fig. 4A). Even on day 28, none of the animals
vaccinated with insufflator developed serum IgG titers. On the
contrary, all animals vaccinated with aerosol generator hadn site is of minor deposition is crucial for hepatitis B vaccination, Acta
Figure 2 In-vivo deposition of dry powder vaccine formulations dispersed from the insufflator and the aerosol generator. Labeled vaccine
powders were pulmonary administered (Pul Pow) to mice by the insufflator or aerosol generator. Immediately after administration, mice were
sacrificed to image intact lungs as well as dissected lung lobes. (A) Schematic representation of trachea and all the lung lobes (LL: left lung lobe;
SL: superior lobe; ML: middle lobe; IL: inferior lobe; PCL: post caval lobe) showing central airways (CA) and deep lung (DL). Representative
IVIS images of the intact as well as dissected lungs of animals that had received influenza (B) and hepatitis B (D) powders from insufflator or
aerosol generator or were left untreated. Untreated animals were used as negative control for imaging calculations and heart was used as an
anatomical negative control due to its proximity to lungs. Quantification of deposition of influenza (C) or hepatitis B (E) powder formulations in
trachea/central airways versus deep lungs of animals (nZ 6). Data are presented as averagestandard error of the mean. Levels of significance
are denoted as ****P  0.0001.
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Upon further quantification of serum IgG1 or IgG2a titers, a
similar trend could be noticed (Fig. 4C). Pulmonary immuniza-
tion with hepatitis B powders dispersed by the aerosol generator
induced both IgG1 and IgG2a titers; as expected no such titers
could be determined for the powders dispersed by the insufflator
(Fig. 4C).
IgG titers were further determined in the lung washes of these
animals. Lung IgG titers were found to be in line with serum IgG
titers. No lung IgG titers were found in the lungs of animalsPlease cite this article as: Tomar J et al., Pulmonary immunization: depositio
Pharmaceutica Sinica B, https://doi.org/10.1016/j.apsb.2019.05.003vaccinated with insufflator whereas the animals vaccinated with
aerosol generator had considerable lung IgG titers (Fig. 4D).
4. Discussion
In the current study, we investigated the influence of the deposi-
tion site of pulmonary administered powder vaccine candidates on
the immunogenicity evoked by these formulations. Powder vac-
cine formulations of influenza and hepatitis B were targeted to
different regions of the respiratory tract by using the insufflatorn site is of minor deposition is crucial for hepatitis B vaccination, Acta
Figure 3 Immune responses induced by dry powder influenza vaccine formulations administered by the insufflator and the aerosol generator.
Mice were immunized twice on day 0 and day 14 with 5 mg of influenza subunit vaccine powder formulation by intramuscular (i.m.) or pulmonary
route. Pulmonary powder formulations were administered by Penn-Insufflator [Pul Pow (PI)] or aerosol generator [Pul Pow (AG)]. Immune
responses were determined on day 14 and day 28. Serum IgG titers on day 14 (A) and on day 28 (B). (C) Lung IgG titers; (D) Lung IgA titers.
Data are presented as averagestandard error of the mean (nZ6).
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+ MODELand an in-house built aerosol generator. The deposition of powder
formulations in different regions of the respiratory tract was
confirmed by an imaging system. The magnitude of immune re-
sponses evoked by these differently targeted/deposited powder
formulations were compared to each other.
Powder administration using the insufflator resulted in depo-
sition in the trachea/central airways whereas administration via the
aerosol generator resulted in a homogeneous distribution
throughout the entire lungs. Since the median diameter (X50) of
the particles dispersed from the aerosol generator was larger than
those dispersed from the insufflator, in principle, the opposite
would be expected in terms of deposition. However, the observed
differences in powder deposition can be ascribed to the differences
in the velocity by which the powder particles were dispersed from
these two different devices. According to manufacturer’s in-
structions, the insufflator’s tip was placed at the bifurcation of
trachea, i.e., the carina. Hence, it can be expected that the powder
particles would have been deposited throughout the whole lung.
However, during insufflation, powder particles were de-
agglomerated and dispersed with 200 mL of air in a single step
within about 2 s. Therefore, the air was introduced at a high ve-
locity to an already inflated lung, which most likely resulted in a
return flow of air containing powder particles. As a result, these
particles were either deposited in the trachea or exhaled (visual
observation).
By contrast, pulmonary administration by aerosol generator is
a two-step process. In the first step, powder particles were de-
agglomerated by allowing the air to enter from the top of thePlease cite this article as: Tomar J et al., Pulmonary immunization: depositio
Pharmaceutica Sinica B, https://doi.org/10.1016/j.apsb.2019.05.003compartment, which allowed the production of an aerosol in the
collection chamber. In the second step, with the introduction of
3 mL of air, powder particles were delivered to the lungs slowly
(1 min) and were being deposited in the lungs of the animals. In
comparison with the insufflator, the velocity of the powder par-
ticles dispersed from the aerosol generator was almost
10  slower (see experimental section). Thus, the return flow of
air was minimized and as a consequence the amount of powder
vaccine deposited in the trachea was found to be quite low. In
addition, the much lower velocity of the powder particles
dispersed by the aerosol generator most likely overcompensated
the fact that the particle size distribution (X50) was larger than that
of the dry powder dispersed by the insufflator.
Immunogenicity studies in mice showed the induction of im-
mune responses of comparable magnitude upon deposition of
influenza vaccine powders either in trachea/central airways or in
the deep lungs. In our previous studies, we found comparable
immune responses induced by pulmonary administration of liquid
and powder influenza vaccine formulations11,12. Our another study
showed that liquid influenza vaccine formulation deposits deep in
the lungs of cotton rats whereas the powder formulation is
deposited in the trachea/central airways upon administration using
the insufflator9. Although this study by Bhide et al.9 demonstrated
differences in deposition, comparable protective efficacy was
induced by liquid and powder influenza vaccine formulations
deposited deep in the lungs or trachea/central airways, respec-
tively9. Consistent with the finding with liquid and powder in our
previous study, we have found in this study that influenza vaccinen site is of minor deposition is crucial for hepatitis B vaccination, Acta
Figure 4 Immune responses induced by dry powder hepatitis B vaccine formulations administered by insufflator and aerosol generator.Micewere
immunized twice on day 0 and day 14 with 2 mg of influenza subunit vaccine powder formulation by intramuscular (i.m.) or pulmonary route.
Pulmonary powder formulations were administered by Penn-Insufflator [Pul Pow (PI)] or aerosol generator [Pul Pow (AG)]. Immune responses were
determined on day 14 and day 28. Serum IgG titers on day 14 (A) and day 28 (B). (C) Serum IgG1 or IgG2a titers; (D) Lung IgG titers. Data are
presented as average  standard error of the mean (nZ 6). Levels of significance are denoted as **P  0.01 and **** or ####P  0.0001.
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+ MODELpowders induce equivalent immune responses upon deposition in
trachea/central airways or deep lungs. However, a study by Minne
et al.7 reported deposition of influenza vaccine in the deep lungs to
be superior to deposition in central airways. Deep lung deposition
was hypothesized to be superior to upper or central airways due to
improved residence time of the antigen as a consequence of
reduced mucociliary clearance. However, the differences in im-
mune responses reported in this study were only found to be
significant between intranasal and deep lung targeted animals7.
Moreover, only liquid influenza vaccine formulation was used; the
physical state of the formulation and the delivery devices used for
administration can also influence deposition of the vaccine
formulation and thus the immune response. Therefore, the results
of studies of Bhide et al.9 and Minne et al.7 cannot be directly
translated to our current study.
Though deep lung targeting does not seem to be essential for
influenza vaccine, the same cannot be concluded for hepatitis B
vaccine. No immune responses were induced when hepatitis B
powders were deposited in the trachea/central airways whereas
the same powder led to considerable immune responses upon
deposition in the deep lungs. Lombry et al.24 studied the efficacy
of DNA vaccines, in particular liquid hepatitis B surface antigen
vaccine, by using two different administration routes. In this
study, it was found that intranasal administration did not result in
the generation of any immune response whereas intratracheal
administration did. Since the aim of this study was only to
investigate efficacy but not the optimal site of hepatitis B
deposition in the respiratory tract, no conclusions were drawn
about it. However, the observed differences found afterPlease cite this article as: Tomar J et al., Pulmonary immunization: depositio
Pharmaceutica Sinica B, https://doi.org/10.1016/j.apsb.2019.05.003administration via different routes could be ascribed to the vol-
ume of the vaccine solution used in the study of Lombry et al.24
Based on the low volume used for intranasal administration, it is
not expected to have resulted in deep lung deposition whereas the
combination of high volume and air bolus in the intratracheal
administration would have caused deep lung deposition24. In
addition, Thomas et al.25 and Minz et al.26 administered liquid
micro-particles or nanoemulsion containing hepatitis B antigen
to the respiratory tract and it resulted in substantial humoral and
cellular immune responses. Because of the high volumes of these
formulations that were administered by intranasal and intra-
tracheal route, we expect that both vaccine formulations were
deposited deep in the lungs of rats. Minz et al.26 concluded that
deep lung deposition elicits stronger immune response; however,
no head to head comparisons were made between immune re-
sponses elicited in upper airways and deep lung targeted animals.
Thus, it would be unreasonable to draw the conclusion that deep
lung deposition elicits a stronger immune response. In the study
by Muttil et al.2, hepatitis B powders were used. Upon dispersion
from the insufflator, significant immune responses were induced
in guinea pigs. This is in contrast to our study. However, the
lungs of guinea pigs are much larger than those of the mice used
in our study. Thus, the relative velocity at which powder particles
entered the lungs must have been much lower. As a consequence,
most likely no or very limited return flow of air occurred and
therefore the powder may have been deposited for a part in the
deep lung although they were administered via the insufflator.
Though the aim of all these studies was not to investigate the
influence of deposition on immune response, based onn site is of minor deposition is crucial for hepatitis B vaccination, Acta
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+ MODELexperimental set-up and results, some conclusions regarding
deposition could already be drawn by us.
For infectious diseases that are transmitted via the respiratory
tract, such as influenza, measles and tuberculosis, both upper/
central airways and deep lungs seem to lead to the induction of
immune responses; however, in a number of studies these re-
sponses were found to be more robust when vaccine was delivered
deep into the lungs7,27e29. Nevertheless, both upper/central air-
ways and deep lung targeting has shown to induce protective ef-
ficacy against lethal viral challenge in pre-clinical animal
models9,27e29. For these infectious diseases, influenza specific
sialic acid, measles specific CD46 and tuberculosis specific
pattern recognition receptors are present in the airways, which
may play a role. In our study, despite of mucociliary clearance,
comparable immune responses induced by powder particles
deposited in trachea/central airways, can be explained by two
reasons. Firstly, the spray-dried influenza formulation contains
inulin in bulk amount, which will readily dissolve upon contact
with the epithelial lining. Inulin, being an oligosaccharide, might
substantially enhance the viscosity at the dissolution site thereby
impeding mucociliary clearance. Secondly, sialic acid receptors
are present in the upper airways of mice30, these receptors might
facilitate recognition of hemagglutinin, the major constituent of
influenza subunit vaccine; thus, alleviating the need of deep lung
targeting of influenza vaccine. Whether the uptake of influenza
vaccine via these receptors leads to an immune response is,
however, still not fully elucidated.
On the other hand, infectious diseases, such as hepatitis B,
mainly spreads via infected blood or body fluids rather than res-
piratory tract. Hence, no hepatitis B specific receptors are present
in the airways, neither in the upper nor in the deeper parts of the
respiratory tract. Thus, the absence of hepatitis B specific re-
ceptors in these regions might have led to the removal of the
vaccine by mucociliary clearance, despite of the high viscosity
caused by the dissolution of inulin in the trachea/central airways;
thus, no immune responses could be generated. However, the
immune responses induced by deep lung targeting could be sub-
stantiated by two reasons. Firstly, Todoroff et al.8 have provided
an evidence of a prolonged residence time of the antigen following
delivery to the deep lungs8; this provides ample time for inter-
action with immune cells to generate an immune response. Sec-
ondly, it is known that hepatitis B surface antigen forms virus like
particles of about 22 nm and particles with a size <30 nm are
known to passively diffuse from alveoli to draining lymph nodes
to induce immune responses31,32.
Interestingly, it seems that for airborne transmitted infections,
diseases that are transmitted via the respiratory tract, deep lung
deposition is not necessary to induce an immune response after
pulmonary vaccination. On the other hand, it seems that for non-
airborne transmitted infections, such as hepatitis B, deep lung
deposition of the vaccine is essential to induce the desired immune
response. From an evolutionary perspective it seems logical that
the type of immune response after pulmonary administration
varies between vaccines against airborne and non-airborne trans-
mitted infectious diseases. Further research should investigate
whether or not this hypothesis holds true for vaccine candidates
against other pathogens that fall under these two categories. For
example, vaccines against air-borne diseases such as pertussis,
respiratory syncytial infection on one hand and against non-
airborne diseases such as cholera, typhoid on the other could be
compared. In addition, for respiratory tract transmitted diseases,
the research should focus on the role of different receptors in thePlease cite this article as: Tomar J et al., Pulmonary immunization: depositio
Pharmaceutica Sinica B, https://doi.org/10.1016/j.apsb.2019.05.003induction of immune responses upon deposition of vaccine for-
mulations in trachea/central airways of pre-clinical animal
models. In addition, it might also be interesting to investigate the
biodistribution of fluorescently labeled vaccine at various time
points. However, limitations like fluorescence attenuation and
mucociliary clearance need to be taken into consideration for long
term distribution experiments. These findings would have signif-
icant implications on the efficacy of pulmonary delivered vaccines
at (pre-)clinical level.
5. Conclusions
In this study, we could achieve deposition of vaccine powder
formulations in the trachea/central airways by insufflator and in
the deep lungs via aerosol generator. Deposition site in the lungs
seems to hold minor relevance for vaccines against infectious
diseases that do spread via the respiratory tract whereas deep lung
vaccine deposition is crucial for infectious diseases that do not
spread via the respiratory tract. It might be due to the presence of
influenza virus/vaccine specific sialic acid receptors and absence
of hep-B-specific receptors in the respiratory tract of mice. Thus,
optimal site of antigen deposition within the respiratory tract
might depend on the type of antigen and the presence/absence of
antigen specific receptors or binding sites in the respiratory tract.
These pre-clinical results hold great potential for future clinical
studies from a mechanistic point of view.Acknowledgments
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